This is a prospective, multicenter, open-label study of human plasma-derived FVIII in previously treated patients with severe hemophilia A. Overall, 55 male PTPs with a FVIII level of less than 1percent and at least 150 treatment exposure days to previous FVIII products will be enrolled.

Patients will undertake a Screening visit between Week 4 to Week 0 to determine their eligibility to be enrolled in the study. All eligible patients will enter the Treatment period of the study to receive study treatment. During the Treatment period- Weeks 1 to 25, patients will receive prophylactic treatment with SKP-0141.

At least the first 12 enrolled patients -PK group, will participate in the PK assessments at Visit 1-single-dose PK,  and Visit 10- steady-state PK. The single-dose PK assessments will be performed at first exposure to SKP-0141- 25 to 50 IU per kg after a minimum of 72-hour washout period, which may be extended up to 96 hours for long half-life FVIII products, from their last marketed FVIII administration. The steady-state PK assessments will be performed around 25 weeks following initiation of prophylactic treatment, subsequent to a minimum of 48-hour washout period from their prophylactic SKP-0141 administration. For PK assessments, patients will undergo blood sampling at predefined time points. If patients experience a bleeding episode (BE) during the initial PK assessment period, they may be treated with their previous FVIII product. Once the BE is controlled the patient may restart the PK assessment following the appropriate washout period from their last marketed FVIII administration.

After the 12 patients in the PK group complete the single-dose PK assessments- Visit 1, the available safety and PK endpoints data will be reviewed by the Independent Data Monitoring Committee to provide recommendations on whether the study should continue. Patient recruitment and enrollment of the patients in the non-PK group will continue during the IDMC review.

Patients will be followed-up for a period of 1 week after completion of Visit 10. The patients will return to the site for the Follow-up visit at Week 26 to document any adverse events or serious adverse events.

A minimum of 10 surgical procedures comprising major surgeries in a least 5 patients will be targeted to assess control and prevention of bleeding in the surgical setting.